Printer Friendly

Browse Empagliflozin topic

Articles

1-163 out of 163 article(s)
Title Author Type Date Words
Safety of the new anti-diabetic medications. Jul 3, 2021 518
Supporting patients on the new diabetes meds: What you need to know. Sparks, Lisa Jul 1, 2021 4049
LATEST COMPANY NEWS. Jun 30, 2021 30696
LATEST COMPANY NEWS. Jun 22, 2021 29479
Metracrine meets full enrollment for MET409 Phase 2a combo trial. Jun 2, 2021 217
SGLT2 inhibitors: A revolution in therapeutics of a Major Non-Communicable Disease. Khan, Muhammad Sami Apr 30, 2021 676
Type 2 diabetes: Two new medications offer fresh management paradigm. Apr 1, 2021 3214
Heart Failure Is a Treatable Condition, Not a Death Sentence: Manage heart failure with medication, a low-sodium diet, and other lifestyle choices to enjoy a full, active life. Mar 31, 2021 1047
Metracrine reports Q4 net loss $10.8M vs. $7.4M a year ago. Financial report Mar 18, 2021 181
SGLT 2 Inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute(MIDEM). Erum Sohail, Tasnim Ahsan, Saima Ghaus and Wasfa Aijaz Feb 24, 2021 3564
Type 2 Diabetes 2021-Beyond Glucose. Brunton, Stephen A. Dec 1, 2020 1735
Statin side effects tied to nocebo effect, study concludes. Stiles, Steve Dec 1, 2020 985
Muscle pain is mostly a nocebo effect of statins, authors say. Stiles, Steve Dec 1, 2020 1157
Heart Failure in Patients with Type 2 Diabetes. Skolnik, Neil; Chuong, Tina Report Dec 1, 2020 6600
Overcoming Therapeutic Inertia: Practical Approaches. Brunton, Stephen A.; Miller, Eden M. Report Dec 1, 2020 6031
CHAPTER-4 - PHARMACOLOGICAL MANAGEMENT OF DIABETES. Nov 30, 2020 2655
Chronic abdominal pain: What to do when a patient presents with it. Paauw, Douglas S. Nov 1, 2020 963
Boehringer Ingelheim, Eli Lilly Tout Full Results of Phase III Trial of Empagliflozin. Sep 1, 2020 518
Current and Emerging Issues in the Management of Heart Failure in Primary Care. Chilton, Robert; Brunton, Stephen Sep 1, 2020 4324
Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician. Bakris, George Sep 1, 2020 5227
A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed. Steinmetz-Wood, Samantha; Gilbert, Matthew; Menson, Katherine Aug 31, 2020 1669
Euglycemic Ketoacidosis in a Patient with Metastatic Non-Small-Cell Lung Adenocarcinoma and Concomitant Pulmonary Embolism. O'Neill, Robert Sean; Tyack, Lauren; Freeman, Mary; Hussein, Hussein Soudy Aug 31, 2020 1927
Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin. Sexe, Jordan; Mayes, Chadwick; Tofts, Peter Jul 31, 2020 2052
Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System. Hu, Yang; Bai, Ziyu; Tang, Yan; Liu, Rongji; Zhao, Bin; Gong, Jian; Mei, Dan Report Jul 31, 2020 5412
The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review. Wu, Chen-Ning; Tien, Kai-Jen Jul 31, 2020 4926
ERTUGLIFLOZIN FOR T2D: Cardiovascular death benefit lacking. Zoler, Mitchel L. Drug overview Jul 1, 2020 1310
Study examines SGLT2 inhibitors vs. GLP-1 receptor agonists in cardiovascular prevention. Busko, Marlene Drug overview Jul 1, 2020 1171
Cardiovascular death benefit lacking with ertugliflozin. Zoler, Mitchel L. Jul 1, 2020 1297
From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management. Pani, Arianna; Gironi, Ilaria; Di Vieste, Giacoma; Mion, Elena; Bertuzzi, Federico; Pintaudi, Basili Report Jun 30, 2020 8704
Boehringer Ingelheim and Eli Lilly sign academic research collaboration for new trial with the Duke Clinical Research Institute. May 27, 2020 318
Boehringer Ingelheim and Eli Lilly sign academic research collaboration for new trial with the Duke Clinical Research Institute. May 27, 2020 314
Daxor announces publication of blood volume outcome data using BVA-100. May 22, 2020 193
SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review. Mouhayyar, Christopher El; Riachy, Ruba; Khalil, Abir Bou; Eid, Asaad; Azar, Sami Drug overview Mar 31, 2020 7163
Boehringer Ingelheim and Eli Lilly granted Fast Track designation for Jardiance for treatment of chronic kidney disease. Mar 13, 2020 272
Boehringer Ingelheim and Eli Lilly granted Fast Track designation for Jardiance for treatment of chronic kidney disease. Mar 13, 2020 268
US FDA grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Kidney Disease. Mar 13, 2020 518
Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature. Sujanani, Sunam M.; Elfishawi, Mohanad M.; Zarghamravanbaksh, Paria; Castillo, Francisco J. Cuevas; Mar 1, 2020 2170
Potential Effects of Empagliflozin in L-NAME--Induced Hypertensive Nephropathy in Albino Rats. Fouqueh, Cherry E.; Labib, Dina A. Aly; Selim, Mohsen S.; Awad, Hisham A. Report Mar 1, 2020 8727
Diabetes Drugs Lower Heart Failure Risk: A new study shows that SGLT2s can help people without diabetes too. Russell, Stuart Feb 1, 2020 583
New Diabetes Drugs a Boon for Patients with Heart Failure: SGLT2 inhibitors go above and beyond lowering blood sugar to prevent heart failure-related deaths and hospitalizations. Feb 1, 2020 712
US FDA approves Trijardy XR. Jan 28, 2020 223
US FDA approves Trijardy XR. Jan 28, 2020 219
Certain Diabetes Meds May Lower Gout Risk, Too. Serena Gordon, HealthDay Reporter Jan 13, 2020 644
End 'therapeutic nihilism' in care of older diabetic patients. Brunk, Doug Jan 1, 2020 1573
ASK THE DOCTORS. Cho, Leslie; Rocco, Michael Jan 1, 2020 580
PSIM to provide common platform to all professional specialty organizations to overcome dearth of leadership-Prof. Javed Akram. Prof. Javed Akram Dec 15, 2019 1297
Dapagliflozin equally effective for those with and without diabetes. Zoler, Mitchel L. Dec 1, 2019 959
A dapagliflozin labeling change comes next. O'Connor, Christopher M. Dec 1, 2019 384
How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area. Canivell, Silvia; Mata-Cases, Manel; Vlacho, Bogdan; Gratacos, Monica; Real, Jordi; Mauricio, Didac; Nov 30, 2019 6844
Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. Mirabelli, Maria; Chiefari, Eusebio; Caroleo, Patrizia; Vero, Raffaella; Brunetti, Francesco Saverio Nov 30, 2019 5361
Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA). Rehani, Peter R.; Iftikhar, Hanaa; Nakajima, Motowo; Tanaka, Tohru; Jabbar, Zaid; Rehani, Riyadh N. Nov 30, 2019 6340
Boehringer Ingelheim--Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised--11/11/2019. Nov 14, 2019 494
Boehringer Ingelheim. Nov 14, 2019 1351
The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing. Shanthi Rexaline Nov 14, 2019 1755
Paragraph IV Patent Certifications Winners and Losers Monthly Report. Report Nov 11, 2019 347
Boehringer Ingelheim. Nov 7, 2019 1349
Boehringer Ingelheim and Eli Lilly to modernise present collaboration. Nov 6, 2019 207
Boehringer Ingelheim and Eli Lilly to modernise present collaboration. Nov 6, 2019 203
Eli Lilly and Company UK (NYSE:LLY) - Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance[R] - 4/11/2019. Nov 6, 2019 508
How to use type 2 diabetes meds to lower CV disease risk: The challenge: Translate evidence from cardiovascular outcomes trials of newer antidiabetic agents into a targeted management strategy. Gotfried, Robert Nov 1, 2019 5930
Eli Lilly and Company UK. Oct 29, 2019 3528
Boehringer Ingelheim. Oct 23, 2019 1352
Eli Lilly & Company (NYSE: LLY). Oct 21, 2019 3791
Boehringer Ingelheim. Oct 17, 2019 1353
Eli Lilly and Company UK. Oct 15, 2019 3523
Morepen Labs adds three new drugs - Rivaroxaban, Vildagliptin and UDCA to its API Portfolio. ANI Oct 14, 2019 821
SGLT2 Inhibitors Protect Against Kidney Disease in T2DM; Reduction seen for risk of dialysis, transplantation, or death due to kidney disease. Oct 10, 2019 237
Boehringer Ingelheim. Oct 10, 2019 1348
Eli Lilly and Company UK. Oct 8, 2019 3528
Eli Lilly & Company (NYSE: LLY). Oct 7, 2019 3493
How to prioritize CV risk reduction in type 2 diabetes. Oct 5, 2019 1162
Boehringer Ingelheim. Oct 2, 2019 1279
Eli Lilly and Company UK. Oct 2, 2019 3523
Eli Lilly & Company (NYSE: LLY). Oct 1, 2019 3488
Semaglutide beats canagliflozin as second-line therapy. Freeman, Sara Drug overview Oct 1, 2019 806
Dapagliflozin transforms from antidiabetic to heart failure drug. Zoler, Mitchel L. Oct 1, 2019 624
Boehringer Ingelheim. Oct 1, 2019 1353
Failure to prevent most heart failure could be avoided. Sep 28, 2019 772
Boehringer Ingelheim. Sep 26, 2019 1274
Eli Lilly and Company UK. Sep 24, 2019 3528
Eli Lilly & Company (NYSE: LLY). Sep 23, 2019 3488
Novo Nordisk's Rybelsus tablets approved by US FDA. Sep 23, 2019 266
Novo Nordisk awarded FDA approval for first oral GLP-1 analog treatment Rybelsus for type 2 diabetes in adults. Sep 23, 2019 241
Novo Nordisk's Rybelsus tablets approved by US FDA. Sep 23, 2019 267
Novo Nordisk awarded FDA approval for first oral GLP-1 analog treatment Rybelsus for type 2 diabetes in adults. Sep 23, 2019 237
US FDA approves Novo Nordisk's Rybelsus tablets 7 mg or 14 mg. Sep 23, 2019 196
US FDA approves Novo Nordisk's Rybelsus tablets 7 mg or 14 mg. Sep 23, 2019 192
Biotech Stock On The Radar: vTv Therapeutics's Diabetes Pipeline. Sep 17, 2019 1319
Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline. Sep 17, 2019 1319
Eli Lilly & Company (NYSE: LLY). Sep 11, 2019 3493
Eli Lilly & Company (NYSE: LLY). Sep 3, 2019 3493
Diabetes medication may protect from heart disease. Sep 1, 2019 369
Early Treatment with Empagliflozin and GABA Improves [beta]-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice. Daems, Caroline; Welsch, Sophie; Boughaleb, Hasnae; Vanderroost, Juliette; Robert, Annie; Sokal, Eti Aug 31, 2019 9093
Boehringer Ingelheim. Aug 29, 2019 1277
Eli Lilly & Company (NYSE: LLY). Aug 27, 2019 3493
Eli Lilly & Company (NYSE: LLY). Aug 20, 2019 3493
Boehringer Ingelheim--First half 2019: High levels of investment in R&D and robust organic growth--1/8/2019. Aug 14, 2019 1159
Boehringer Ingelheim. Aug 14, 2019 1275
Eli Lilly & Company (NYSE: LLY). Aug 13, 2019 3493
Boehringer Ingelheim--First half 2019: High levels of investment in R&D and robust organic growth--1/8/2019. Aug 7, 2019 1159
Boehringer Ingelheim. Aug 7, 2019 1275
Eli Lilly & Company (NYSE: LLY). Aug 6, 2019 3493
Could diabetes drug treat heart patients? Jul 15, 2019 433
Could diabetes drug treat heart patients? DR MIRIAM STOPPARD Helping to keep you fit and healthy miriam@mirror.co.uk @MiriamStoppard. Jul 15, 2019 433
Eli Lilly & Company (NYSE: LLY) - U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure -- 26/6/2019. Jul 4, 2019 491
ASK THE DOCTORS. Cho, Leslie; Strawbridge, Holly Jul 1, 2019 762
TYPE 2 DIABETES: The costs and benefits of SGLT2 inhibitors & GLP-1 RAs. Dotinga, Randy; Lennon, Katie Jul 1, 2019 3539
TYPE 2 DIABETES: The costs and benefits of SGLT2 inhibitors & GLP-1 RAs. Dotinga, Randy; Lennon, Katie Jul 1, 2019 3536
A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes. Hassani-Ardakania, Kimya; Lipman, Mark L.; Laporta, Denny; Yu, Oriana Hoi Yun Jun 30, 2019 2355
US FDA grants Boehringer Ingelheim and Eli Lilly fast track designation for Empagliflozin. Jun 28, 2019 207
US FDA grants Boehringer Ingelheim and Eli Lilly fast track designation for Empagliflozin. Jun 28, 2019 203
Iran Unveils 7 New Knowledge-Based Products. Jun 19, 2019 467
Iran Unveils 9 New Home-Made Hi-Tech Drugs. Jun 18, 2019 405
Full Data from CAROLINA Outcome Trial Support Long-Term Cardiovascular Safety Profile of Trajenta. Jun 12, 2019 856
Iran Boasts 3.3% Rise in Medicine Production. Jun 6, 2019 518
Management of Type 2 Diabetes Mellitus with Overweight: Focus on SGLT-2 Inhibitors and GLP-1 Receptor Agonists. Jargin, Sergei V. Jun 1, 2019 3898
SGLT2 inhibitors prevent HF hospitalization regardless of baseline LVEF. Jancin, Bruce Jun 1, 2019 404
Weight-loss drug options expand, but cardiac risks exist. Dotinga, Randy Jun 1, 2019 979
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. Papadokostaki, Eleni; Liberopoulos, Evangelos May 31, 2019 3214
Iran Industrializes Home-Made Drug to Treat Liver Cancer. May 12, 2019 390
ADA recommends cardioprotective antihyperglycemic drugs for patients. May 11, 2019 1086
Iran Unveils 4 New Drugs for Treating Cancer, Diabetes. May 7, 2019 551
Iran Vows to Indigenize Sanctioned Medicine. May 7, 2019 661
Iran Develops Know-How for Production of 4 Vital Cancer, Diabetes Drugs. May 6, 2019 427
The Effects of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2-i) on Fatty Liver, Steato-Hepatitis, Liver Fibrosis, and Hepatocellular Carcinoma-A Review. Mirghani, Hyder Osman; Thaniyath, Thomas Antony; Elfakki, Fakhralddin Abbas Clinical report May 1, 2019 3235
Efficacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin. Apr 30, 2019 3200
Expert Opinion: Use of sodium glucose co-transporter type-2 inhibitors in South Asian population-The Pakistan perspective. Report Apr 30, 2019 6076
Novo Nordisk announces submission of MAA to EU for oral semaglutide for the treatment of type 2 diabetes. Apr 29, 2019 189
Novo Nordisk announces submission of MAA to EU for oral semaglutide for the treatment of type 2 diabetes. Apr 29, 2019 185
Biological Safety Studies and Simultaneous Determination of Linagliptin and Synthetic Impurities by LC-PDA. Balestri Heleno Ferreira, Raquel; Apollo Duarte, Jonathaline; Dias Ferreira, Flavio; Flavio Souza de Mar 31, 2019 6888
Micro- and Macrovascular Complications in Diabetes Mellitus: Preclinical and Clinical Studies. Rangel, Erika B.; Rodrigues, Claudia O.; De Sa, Joao R. Clinical report Mar 31, 2019 3343
Diabetes Is a Major Risk Factor for Heart Disease: Lifestyle modifications can help protect your heart health. Mar 30, 2019 767
Boheringer and Lilly present initial results of empagliflozin compared with DPP-4 inhibitors study at ACC.19 and AMCP 2019. Mar 29, 2019 275
Boheringer and Lilly present initial results of empagliflozin compared with DPP-4 inhibitors study at ACC.19 and AMCP 2019. Mar 29, 2019 271
Novo Nordisk submits two NDAs to US FDA for oral semaglutide and sNDA for Ozempic. Mar 21, 2019 414
Novo Nordisk submits two NDAs to US FDA for oral semaglutide and sNDA for Ozempic. Mar 21, 2019 415
Novo Nordisk submits two NDAs to US FDA for oral semaglutide and sNDA for Ozempic. Mar 21, 2019 410
Boehringer Ingelheim. Mar 20, 2019 1015
Novo Nordisk reports submission of two NDAs to FDA for oral semaglutide. Mar 20, 2019 266
The Effects of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT-2-i) on Fatty Liver, Steato-Hepatitis, Liver Fibrosis, and Hepatocellular Carcinoma-A Review. Mirghani, Hyder Osman; Thaniyath, Thomas Antony; Elfakki, Fakhralddin Abbas Clinical report Mar 1, 2019 3338
How do these 3 diabetes agents compare in reducing mortality? A meta-analysis reveals that there may be advantages associated with SGLT-2 inhibitors and GLP-1 agonists that are not associated with DPP-4 inhibitors. Martini, Jennifer; Coe, Catherine L.; Mounsey, Anne Report Mar 1, 2019 1736
SGLT2 INHIBITORS: Benefits in heart failure. Jancin, Bruce Mar 1, 2019 928
SGLT2 inhibitors may increase the risk of serious adverse events. Drug overview Feb 28, 2019 692
Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes. Miller, Eden M.; Wysham, Carol H. Report Aug 1, 2018 4907
A Role for Branched-Chain Amino Acids in the Pathophysiology of Diabetes: Using Data to Guide Discovery. Katz, Daniel H.; Gerszten, Robert E. Aug 1, 2018 1110
Empagliflozin Doesn't Up Risk of Bone Fractures; Per pooled data from placebo-controlled trials and data from a head-to-head study with glimepiride. Jul 20, 2018 237
Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy. Herat, Lakshini Y.; Matthews, Vance B.; Rakoczy, P. Elizabeth; Carnagarin, Revathy; Schlaich, Markus Jan 1, 2018 5962
Cardiac Complications of Diabetes. Khalil, Charbel Abi; Al Suwaidi, Jassim; Refaat, Marwan; Mohammedi, Kamel Jan 1, 2018 1136
Tiaolipiwei Acupuncture Reduces Albuminuria by Alleviating Podocyte Lesions in a Rat Model of Diabetic Nephropathy. Zhang, Zhilong; Li, Xinju; Liu, Liang; Sun, Jiya; Wang, Xu; Zhao, Zhiheng; Yang, Yuanqing Jan 1, 2018 6114
Comparison of General Practice and Pharmaceutical Dispensing Data for Pharmacoepidemiological Research: Assessing the Risk of Urinary-Tract Infections with Sodium Glucose Cotransporter 2 Inhibitors for Diabetes. Gadzhanova, Svetla; Roughead, Elizabeth Clinical report Jan 1, 2018 3552
Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis. Badwal, Karun; Tariq, Tooba; Peirce, Diane Jan 1, 2018 2595
Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. Batzias, Konstantinos; Antonopoulos, Alexios S.; Oikonomou, Evangelos; Siasos, Gerasimos; Bletsa, Ev Report Jan 1, 2018 7182
Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy. Moura, Cristiano S.; Rosenberg, Zale B.; Abrahamowicz, Michal; Bernatsky, Sasha; Behlouli, Hassan; P Jan 1, 2018 4531
Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy. Cho, Eun Hyung; Park, Se-Jun; Han, Seongwook; Song, Ji Hun; Lee, Kihwang; Chung, Yoo-Ri Jan 1, 2018 4574
Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective. Farahani, Pendar Jan 1, 2018 5597
Intranasal Insulin Administration Does Not Affect LH Concentrations in Men with Diabetes. Dhindsa, Sandeep; Chemitiganti, Rama; Ghanim, Husam; Santiago, Evangelina; Haider, Adnan; Chaar, Nat Jan 1, 2018 5526
Quality of Methodological Reporting of Randomized Clinical Trials of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors. Alfahmi, Hadeel; Aldawood, Lina; Baz, Bayan; Elrggal, Mahmoud; Alsharif, Hadeel Yahya; Alkahtani, Sa Apr 1, 2017 2298
Overview of the efficacy and safety of SGLT-2 inhibitors in type 2 diabetes mellitus. Miller, Eden M. Report Feb 1, 2017 5967
Empagliflozin surpasses glimepiride as metformin add-on. Mark Kirkner, Richard Jul 1, 2016 794
No home run yet. Karon, Amy Brief article Jul 1, 2016 246
Empagliflozin spared kidney function in 2DM. Brunk, Doug Report Dec 1, 2015 971
Empagliflozin okayed for type 2 diabetes. Mechcatie, Elizabeth Brief article Aug 1, 2014 287
Empagliflozin improves glycemia, blood pressure. Mechcatie, Elizabeth Jun 1, 2014 622

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |